Global registry tracks Real-World safety of gut drug
NCT ID NCT01990040
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This registry follows about 1,800 people with short bowel syndrome (SBS) to see how safe and effective the drug teduglutide is over the long term in everyday medical practice. It includes both patients who take teduglutide and those who do not. The main goal is to monitor for colorectal cancer and other serious side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- teduglutide
- What this could lead to
- If successful, this registry could provide a clearer picture of the long-term safety and effectiveness of teduglutide for managing short bowel syndrome.
- What could go wrong
- This is an observational registry, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by differences in patient care or other factors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SHORT BOWEL SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shire
Lexington, Massachusetts, 02421, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Measuring hidden energy needs: a clue to better nutrition for gut failure patients
- Weekly shot could help people with short bowel syndrome absorb more fluids
- New drug could cut IV nutrition needs for short bowel patients
- Could a Plant-Based powder cut the need for IV nutrition?
- Growth hormone shows promise for weaning kids off IV nutrition
- New drug teduglutide monitored in 250 patients with short bowel syndrome